Bacteriophage strain capable of producing a lytic infection in the Escherichia coli ST131-025B:H4 clone

US11041147B2 · kind B2 · utility

Assignees

• INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR
• ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS (APHP) · FR
• UNIVERSITÉ PARIS DIDEROT—PARIS 7 · FR
• Universite Paris XIII Paris-Nord · FR

Inventors

• Jean-Damien Ricard · Paris, FR
• Olivier Clermont · Paris, FR
• Laurent Debarbieux · Paris, FR
• Erick Denamur · Paris, FR
• Nicolas Dufour · Cergy, FR

Key dates

• Filing date: Apr 12, 2017
• Grant date: Jun 22, 2021
• Expiry date: Aug 8, 2037

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a bacteriophage strain capable of producing a lytic infection in the Escherichia coli ST131-025b:H4 clone. The burden of ST131-025b:H4 Escherichia coli clonal complex in human community and hospital-acquired infections is increasing worldwide, going along with a worrying and growing resistance to betalactams and fluoroquinolones. Bacteriophage LM33_P1 infects exclusively (100% specificity) 025b E. coli strains with 70% coverage on the two major antibiotic resistant pandemic clonal complexes ST131-025b:H4 and ST69-025b. The inventors evaluated the in vivo activity of bacteriophage LM33_P1 using three different extraintestinal virulence murine models and showed that it infects bacteria in several organs. In particular, the invention relates to a bacteriophage capable of producing a lytic infection in the Escherichia coli ST131-025b:H4 clone comprising a polypeptide corresponding to the bacteriophage tail fiber protein and responsible for the attachment of the bacteriophage to the Escherichia coli ST131-025b:H4 clone.